Heparin-induced thrombocytopenia resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 84: Line 84:


==Special Considerations==
==Special Considerations==
Shown below is a table summarizing the appropriate choice of anticoagulation therapy in special situations.<ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=PMC3278058 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270  }} </ref>
{| class="wikitable"
{| class="wikitable"
|-
|-
| '''Special situations''' || '''Acute HIT or subacute HIT (normal platelets and positive antibodies)''' || '''Past medical history of HIT'''
| '''Special situations''' || '''Acute HIT or subacute HIT (normal platelets and positive antibodies)''' || '''Past medical history of HIT'''
|-
|-
| '''[[Cardiac surgery]]''' || <u>Urgent cardiac surgery</u>: Use bivalirudin<br> <u>Non urgent cardiac surgery</u>: Delay the surgery until HIT has resolved and antibodies are negative|| <u>Negative antibodies</u>: Use heparin (short term) <br> <u>Positive antibodies</u>: Use bivalirudin
| '''[[Cardiac surgery]]''' || <u>Urgent cardiac surgery</u>: Use [[bivalirudin]]<br> <u>Non urgent cardiac surgery</u>: Delay the surgery until HIT has resolved and antibodies are negative|| <u>Negative antibodies</u>: Use [[heparin]] (short term) <br> <u>Positive antibodies</u>: Use [[bivalirudin]]
|-
|-
| '''[[PCI]]'''|| Use bivalirudin or argatraban ||Use bivalirudin or argatraban
| '''[[PCI]]'''|| Use [[bivalirudin]] or [[argatraban]] ||Use [[bivalirudin]] or [[argatraban]]
|-
|-
| '''[[Dialysis|Renal replacement therapy]]'''||Use argatroban or danaproid || Use regional citrate
| '''[[Dialysis|Renal replacement therapy]]'''||Use [[argatroban]] or [[danaproid]] || Use regional citrate
|-
|-
| '''[[Pregnancy]]''' ||Use danaproid|| N/A
| '''[[Pregnancy]]''' ||Use [[danaproid]]|| -
|-
|-
|}
|}
==Management==
Shown below is an algorithm summarizing the approach to [[heparin induced thrombocytopenia]]. <ref name="pmid16928996">{{cite journal| author=Arepally GM, Ortel TL| title=Clinical practice. Heparin-induced thrombocytopenia. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 8 | pages= 809-17 | pmid=16928996 | doi=10.1056/NEJMcp052967 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16928996  }} </ref> <ref name="pmid22246036">{{cite journal| author=Cuker A, Cines DB| title=How I treat heparin-induced thrombocytopenia. | journal=Blood | year= 2012 | volume= 119 | issue= 10 | pages= 2209-18 | pmid=22246036 | doi=10.1182/blood-2011-11-376293 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22246036  }} </ref> <ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=PMC3278058 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270  }} </ref>
<br>
{{familytree/start |summary=Heparin Induced Thrombocytopenia Managment Algorithm. }}
{{familytree | | | | | | | | | | | | K01 | | | | | | | | | | | | | | | | | | | | | | | | | | |K01='''Thrombocytopenia:'''<br><div style="float: left; text-align: left; line-height: 150% "> ❑ Platelet count <150,000/mm<sup>3</sup> or <br> ❑ >50% decrease from highest level before initiation of heparin therapy <br> ❑ Making sure patient has received heparin or [[LMWH]] in the previous 5- 14 days <br> ❑ And after ruling out other causes of [[thrombocytopenia]] <br> </div>}} }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | | | | |A01='''High or intermediate clinical suspicion of HIT'''<br><div style="float: left; text-align: left; line-height: 150% "> ❑ Venous/arterial thrombosis<br>❑ Unusual manifestations:
*Skin necrosis at SC heparin injection sites
*Transient global amnesia<br>
❑ Abscence of petechiae and/or significant bleeding<br> </div>}}
{{familytree | | | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | B01 | | | | | |B01='''Discontinue [[heparin]]''' }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | |,| A01 |-| A02 | |A01=[[Lepirudin]]:
❑Bolus:0.2 mg/kg (only for life- or limb- threatening thrombosis)
❑Continuous infusion:
*Cr < 1.0 mg/dl → 0.10 mg/kg/h
*Cr 1.0-1.6 mg/dl → 0.05 mg/kg/h
*Cr 1.6-4.5 mg/dl → 0.01 mg/kg/h
*Cr > 4.5 mg/dl → 0.005 mg/kg/h|A02=Measure [[aPTT]] 2 hrs after therapy and after each dose adjustment. Optimal aPTT<65 sec. Check baseline before starting [[warfarin]].  }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | |,|-| B01 |-|+| B02 |-| B03 | |B01=[[Direct thrombin inhibitors]] |B02=[[Argatroban]]:
❑Bolus:None
❑Continuous infusion:
*Normal organ function → 2 mcg/kg/min
*Liver dysfunction (total serum bilirubin >1.5 mg/dl), heart failure, post-cardiac surgery, anasarca → 0.5-1.2 mcg/kg/min|B03=Measure [[aPTT]] 2 hrs after therapy and after each dose adjustment. Switching to [[warfarin]] complicated due to prolonged [[PT]]. }}
{{familytree | | | | | | | | | | | | |!| | |!| | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | |!| | | | | |`| C01 |-| C02 | |C01=[[Bivalirudin]]:
❑Bolus: None
❑Continuous infusion:
*Normal organ function → 0.15 mg/kg/h
*Renal or hepatic dysfunction → dose reduction may be appropriate|C02=Measure ACT 5 min after completing IV bolus }}
{{familytree | | | | | | | | | | | | |!| | |!| | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | C01 |-|(| | | | | | | | | | | |C01='''Initiate alternative anticoagulant therapy for at least 2-3 months''' }}
{{familytree | | | | | | | | | | | | |!| | |!| | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | |!| | | | | |,| A01 |-| A02 | |A01=[[Danaparoid]]|A02=Monitoring not needed. If needed maintain anti-factor Xa 0.5-0.8 U/mL | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | |!| | |!| | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | |`|-| D01 |-|(| | | | |D01=Anti-factor Xa therapy }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | |`| B01 | |B01=[[Fondaparinux]] }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | P01 | | | | | | | | | | | | | | | | | | | | | | | | | | |P01=Proceed to serologic testing}}
{{familytree | | | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | |,|-|-|-|v|-|^|-|-|v|-|-|-|.| | | | | | }}
{{familytree | | | | | | |!| | | |!| | | | |!| | | |!| | | | }}
{{familytree | | | | | | Q01 | | Q02 | | | Q03 | | Q04 | | | | | | | | | | | | | | | | | | | | |Q01=Positive + high clinical suspicion of HIT |Q02=Positive + intermediate suspicion of HIT |Q03=Negative + high clinical suspicion of HIT |Q04=Negative + intermediate clinical suspicion of HIT }}
{{familytree | | | | | | |!| | | |!| | | | |!| | | |!| | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | R01 | | R02 | | | R03 | | R04 | | | | | | | | | | | | | | | | | | | | |R01=Confirmed HIT |R02=Proceed to functional testing |R03=Indeterminate HIT |R04=Can restart heparin }} 
{{familytree | | | | | | | | | | |!| | | | |!| | | |!| ||}}
{{familytree | | | | | | |,|-|-|-|^|-|-|.| |!| | | |!| | }}
{{familytree | | | | | | |!| | | | | | |!| |!| | | |!| | | | }}
{{familytree | | | | | | Q01 | | | | | Q02 |!| | | |!| | | | | | | | | | | | | | | | |Q01=C-Serotonin Release Assay (SRA) |Q02=Heparin induced platelet-activation assays (HIPA) }}
{{familytree | | | | | | | | | | | | | | | |!| | | |!| | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | S01 | | S02 | | | | | | | | | | | | | | | | | | | | |S01=Rule out other causes of thrombocytopenia |S02=Rule out other causes of thrombocytopenia }}
{{familytree/end}}


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 15:27, 2 January 2014

Resident Survival Guide
Introduction
Team
Guide
Page Template
Examine the Patient Template
Navigation Bar Template
Checklist
Topics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Karol Gema Hernandez, M.D. [2]

Definition

Heparin induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that predisposes to elevated risks of arterial and venous thromboembolism.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Screening for HIT

 
 
Asses the risk of HIT
 
 
 
 
 
 
 
 
 
 
 
 
Patient Population (Minimum of 4-d Exposure)Incidence of HIT, %
Postoperative patients
Heparin, prophylactic dose1-5
Heparin, therapeutic dose1-5
Heparin, flushes0.1-1
LMWH, prophylactic or therapeutic dose0.1-1
Cardiac surgery patients1-3
Medical patients
Patients with cancer1
Heparin, prophylactic or therapeutic dose0.1-1
LMWH, prophylactic or therapeutic dose0.6
Intensive care patients0.4
Heparin, flushes< 0.1
Obstetrics patients <0.1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk <1%
 
Risk >1%
 
 
 
 
 
 
 
 
 
 
❑ Do not monitor platelet count
 
❑ Monitor platelet count every 2 or 3 days from day 4 to day 14 (or until heparin is stopped)

Algorithm based on the 2012 ACCP evidence based clinical practice guidelines.[1]

Diagnostic Approach to HIT

 
 
 
Thrombocytopenia
❑ Platelet count <150,000/mm3, OR
❑ >30-50% decrease decrease of platelet from baseline
❑ Recent heparin or LMWH use in the previous 5- 14 days
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms (if present):
❑ Arterial thromboembolism
❑ Venous thromboembolism
❑ Unusual manifestations:

- Skin necrosis at SC heparin injection sites
- Transient global amnesia

❑ Absence of petechiae and/or significant bleeding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suspicion of HIT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low clinical probability
 
 
 
Intermediate/high clinical probability
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unlikely HIT
❑ Consider alternative diagnoses
❑ Continue heparin
 
 
 
❑ Discontinue heparin
❑ Begin alternative anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Order anti PF4 antibodies
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moderately/strongly positive test
 
Weakly positive test
Plus
High clinical probability
 
Weakly positive test
PLUS
Intermediatre clinical probability
 
Negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Order functional assay
 
 
 
 
 
Unlikely HIT
❑ Consider alternative diagnoses
❑ Continue heparin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive test
Likely HIT
 
Negative test
HIT undetermined
 
 
 
 
 
 
 
 


The most studied functional assays are serotonin release assay (SRA) and Heparin induced platelet activation assay (HIPA).[2]

The diagnostic algorithm is based on "How I treat heparin-induced thrombocytopenia" from Blood (2012).[2]

Special Considerations

Shown below is a table summarizing the appropriate choice of anticoagulation therapy in special situations.[1]

Special situations Acute HIT or subacute HIT (normal platelets and positive antibodies) Past medical history of HIT
Cardiac surgery Urgent cardiac surgery: Use bivalirudin
Non urgent cardiac surgery: Delay the surgery until HIT has resolved and antibodies are negative
Negative antibodies: Use heparin (short term)
Positive antibodies: Use bivalirudin
PCI Use bivalirudin or argatraban Use bivalirudin or argatraban
Renal replacement therapy Use argatroban or danaproid Use regional citrate
Pregnancy Use danaproid -

References

  1. 1.0 1.1 Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S; et al. (2012). "Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e495S–530S. doi:10.1378/chest.11-2303. PMC 3278058. PMID 22315270.
  2. 2.0 2.1 Cuker A, Cines DB (2012). "How I treat heparin-induced thrombocytopenia". Blood. 119 (10): 2209–18. doi:10.1182/blood-2011-11-376293. PMID 22246036.